Last reviewed · How we verify
NCT07272616: GDW
Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
trial testing Novel Gadolinium-Weighted MRI Sequence in Brain Neoplasms in 100 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Region Stockholm |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 28 January 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Novel Gadolinium-Weighted MRI Sequence
Conditions studied
- Brain Neoplasms — all drugs for Brain Neoplasms →
Sponsor
Region Stockholm — full company profile →
Who can join
18 and older, any sex, with Brain Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07272616
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Neoplasms
Currently open trials in the same condition.
- NCT07426848 — OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients · NA · recruiting
- NCT07111182 — Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery · NA · recruiting
- NCT07238322 — [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes · active not recruiting
- NCT06165653 — Guided Meditation During Radiation Therapy for Brain Tumors · NA · recruiting
- NCT06273176 — The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma · recruiting
Other Region Stockholm trials
Trials by the same sponsor.
- NCT06304363 — Braining - Evaluation of Acute Effects of Physical Exercise · NA · not yet recruiting
- NCT07089771 — Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy · NA · not yet recruiting
- NCT07503951 — Cognitive Behavior Therapy in Psychiatric Inpatient Care · NA · not yet recruiting
- NCT07434219 — A Group Based Psychoeducational Intervention for Partners of Child Sexual Abuse Material Offenders. · NA · not yet recruiting
- NCT07464730 — Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07272616 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Stockholm
- Last refreshed: 30 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07272616.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing